Respiratory Syncytial Virus Infection Clinical Trial
Official title:
A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-label Lead-in Part Followed by a Double-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability and Clinical Activity of ALX-0171, Administered Via Inhalation, in Addition to Standard of Care.
The primary objective of the study is to investigate the safety and tolerability of ALX-0171.
The secondary objectives are to evaluate the clinical effect of ALX-0171 and to explore the
pharmacodynamics (PD) and the systemic pharmacokinetics (PK) of ALX-0171.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02016690 -
Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immuno Compromised Children With Synagis
|
N/A | |
| Completed |
NCT01107535 -
Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection
|
N/A | |
| Completed |
NCT04491877 -
Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
|
Phase 2 | |
| Completed |
NCT05987072 -
A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.
|
Phase 1 | |
| Completed |
NCT01006629 -
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
|
Phase 2/Phase 3 | |
| Completed |
NCT00593918 -
Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children
|
N/A | |
| Recruiting |
NCT06134648 -
Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate
|
Phase 1/Phase 2 | |
| Completed |
NCT03473002 -
A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT02135614 -
Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
|
Phase 2 | |
| Completed |
NCT01909843 -
ALX-0171 Safety Study in Adults With Hyperresponsive Airways
|
Phase 1 | |
| Recruiting |
NCT06206720 -
A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV
|
Phase 2 | |
| Completed |
NCT02254421 -
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
|
Phase 2 | |
| Recruiting |
NCT06237296 -
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
|
Phase 1 | |
| Completed |
NCT01537198 -
Surveillance of Synagis in Korean Pediatric Patients
|
N/A | |
| Recruiting |
NCT05687279 -
Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)
|
Phase 1/Phase 2 | |
| Completed |
NCT01297504 -
A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America
|
N/A | |
| Recruiting |
NCT06079320 -
A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06194318 -
First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01466062 -
Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions
|
Phase 3 | |
| Active, not recruiting |
NCT04767373 -
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
|
Phase 2/Phase 3 |